

Transparency notification BlackRock, Inc.

Brussels (Belgium), 12 March 2025 – 20:00 (CEST) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 11 March 2025.

BlackRock, Inc. notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold upwards on 10 March 2025.

On 10 March 2025, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 725 971 UCB shares with voting rights and 126.101 assimilated financial instruments, representing together 5.07% of the total number of shares issued by the company (194 505 658), versus 5.10% (9 699 063 UCB shares and 215 582 assimilated financial instruments) in the previous notification dated 7 March 2025.

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada



UCB News

BlackRock Asset Management Deutschland AG	Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Investment Management (Australia) Limited	Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan
Aperio Group, LLC	3 Harbor Dr Suite 204, Sausalito, CA 94965, U.S.A.
SpiderRock Advisors, LLC	Corporation Service Company, 251 Little Falls Drive, Wilmington, DE 19808, U.S.A.

- **Date on which the threshold is crossed:** 10 March 2025.
- **Threshold crossed (in %):** 5%.
- **Denominator:** 194 505 658.

- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc.	0	0		0,00%	
BlackRock (Netherlands) B.V.	1.337	1.337		0,00%	
BlackRock (Singapore) Limited	10.538	9.601		0,00%	
BlackRock Advisors (UK) Limited	1.623.556	1.622.142		0,83%	
BlackRock Advisors, LLC	201.535	201.535		0,10%	
BlackRock Asset Management Canada Limited	138.714	138.719		0,07%	
BlackRock Asset Management Deutschland AG	181.285	179.060		0,09%	
BlackRock Asset Management North Asia Limited	3.080	3.080		0,00%	
BlackRock Financial Management, Inc.	73.923	73.923		0,04%	
BlackRock Fund Advisors	2.445.575	2.447.918		1,26%	
BlackRock Institutional Trust Company, National Association	1.602.340	1.601.607		0,82%	
BlackRock Investment Management (Australia) Limited	51.478	51.564		0,03%	

UCB News

BlackRock Investment Management (UK) Limited	2.508.775	2.550.434		1,31%	
BlackRock Investment Management, LLC	645.042	633.166		0,33%	
BlackRock Japan Co., Ltd.	170.111	170.111		0,09%	
Aperio Group, LLC	41.774	41.774		0,02%	
Subtotal	9.699.063	9.725.971		5,00%	
	TOTAL	9.725.971	0	5,00%	0,00%

B) Equivalent financial instruments	After the transaction						
	Holdings of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Investment Management (UK) Limited	Securities Lent				113.548	0,06%	physical
BlackRock Investment Management, LLC	Securities Lent				2.954	0,00%	physical
BlackRock Financial Management, Inc.	Contract Difference				1.165	0,00%	cash
BlackRock Institutional Trust Company, National Association	Contract Difference				2.148	0,00%	cash
BlackRock Investment Management (UK) Limited	Depository Receipt				229	0,00%	



UCB News

Aperio Group, LLC	Depository Receipt			6.024	0,00%	
SpiderRock Advisors, LLC	Depository Receipt			33	0,00%	
	TOTAL			126.101	0,06%	

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	9.852.071	5,07%

- **Chain of controlled undertakings through which the holding is effectively held:** Please see the full chain of control in the 'Chain of Control' tab.
- **Additional information:** The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc going above 5%

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations
Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news